Besse B - Search Results

1

Dabrafenib plus trametinib in patients with previously untreated BRAF^V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Planchard D, et al. Among authors: besse b. Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11. Lancet Oncol. 2017. PMID: 28919011 Clinical Trial.

2

[Neoadjuvant chemotherapy in non small cell lung cancer].

Besse B, Vignot S, Le Chevalier T. Besse B, et al. Bull Cancer. 2006 Nov;93(11):1087-92. Bull Cancer. 2006. PMID: 17145577 Free article. Review. French.

3

[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].

Italiano A, Besse B, Planchard D, Soria JC. Italiano A, et al. Among authors: besse b. Bull Cancer. 2007;94(7 Suppl):F177-88. Bull Cancer. 2007. PMID: 17964994 Review. French.

4

[Angiogenesis targeting in lung cancers].

Planchard D, Besse B. Planchard D, et al. Among authors: besse b. Bull Cancer. 2007;94(7 Suppl):F217-22. Bull Cancer. 2007. PMID: 17964999 Review. French.

5

Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers.

Mountzios G, Planchard D, Besse B, Validire P, Girard P, Devisme C, Dimopoulos MA, Soria JC, Fouret P. Mountzios G, et al. Among authors: besse b. Clin Cancer Res. 2008 Jul 1;14(13):4096-102. doi: 10.1158/1078-0432.CCR-07-4150. Clin Cancer Res. 2008. PMID: 18593986

6

[Towards customized therapy for non small cell lung cancer].

Planchard D, Besse B. Planchard D, et al. Among authors: besse b. Bull Cancer. 2008 Oct;95(10):951-8. doi: 10.1684/bdc.2008.0719. Bull Cancer. 2008. PMID: 19004725 Free article. French.

7

Adjuvant or induction cisplatin-based chemotherapy for operable lung cancer.

Besse B, Le Chevalier T. Besse B, et al. Oncology (Williston Park). 2009 May;23(6):520-7. Oncology (Williston Park). 2009. PMID: 19544693 Review.

8

Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.

Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC. Gomez-Roca C, et al. Among authors: besse b. J Thorac Oncol. 2009 Oct;4(10):1212-20. doi: 10.1097/JTO.0b013e3181b44321. J Thorac Oncol. 2009. PMID: 19687761 Free article.

9

Use of adjuvant chemotherapy in non-small cell lung cancer in routine practice.

Massard C, Tran Ba Loc P, Haddad V, Pignon JP, Girard P, Monnet I, Trédaniel J, Besse B, Soria JC. Massard C, et al. Among authors: besse b. J Thorac Oncol. 2009 Dec;4(12):1504-10. doi: 10.1097/JTO.0b013e3181bbf1c9. J Thorac Oncol. 2009. PMID: 19745763 Free article.

10

Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.

Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, Reese D, Wiezorek J, Blackhall F. Soria JC, et al. Among authors: besse b. J Clin Oncol. 2010 Mar 20;28(9):1527-33. doi: 10.1200/JCO.2009.25.4847. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159815 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

582 results

Search Page